title: Protection against paracetamol-induced hepatic injury by prazosin pre-treatment in CD-1 mice.
abstract: A synergistic depletion of glutathione has been suggested to be one critical factor in the hepatic injury in mice induced by non-toxic doses of paracetamol (APAP) when co-administered with alpha-adrenergic agonists. Prazosin (an alpha-adrenergic antagonist) could confer hepatoprotection following a toxic APAP dose (530 mg/kg) by increasing glutathione levels and enhancing bioinactivation by glucuronidation and glutathione conjugation. The effect of prazosin pre-treatment on APAP-induced gluthathione depletion and bioinactivation in vivo was assessed. Prazosin (15 mg/kg) pre-treatment provided protection against APAP-induced hepatic injury as evidenced by a significant decrease in serum transaminase (ALT) levels after 5h (p<0.05). Interestingly, prazosin pre-treatment did not prevent the dramatic depletion of glutathione by high dose APAP and it had no effect on the quantity of the glutathione conjugate formed. However, prazosin pre-treatment caused a significant increase in recovery of the administered dose (530 mg/kg) as the glucuronide metabolite (p<0.05). UDP-glucuronosyltransferase (UGT) is involved in the bioinactivation of APAP by glucuronidation and we showed that prazosin had no effect on microsomal UGT kinetics. Thus, prazosin had no effect on either APAP-mediated glutathione depletion or the extent of APAP-glutathione conjugate formation and may be affecting other mechanisms to reduce oxidative stress caused by a toxic dose of APAP.
authors.affiliation: Pharmacology Unit, Faculty of Medical Sciences, The University of the West Indies, Trinidad and Tobago. yuriclem@yahoo.com
authors.forename: Yuri N
authors.initials: YN
authors.lastname: Clement
authors.forename: Arlene F
authors.initials: AF
authors.lastname: Williams
mesh_terms: D000082:Acetaminophen / Q000009:adverse effects*; D000316:Adrenergic alpha-Agonists / Q000009:adverse effects; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000410:Alanine Transaminase / Q000097:blood / Q000187:drug effects; D018712:Analgesics, Non-Narcotic / Q000009:adverse effects; D000818:Animals; D016227:Benzoquinones / Q000378:metabolism; D056486:Chemical and Drug Induced Liver Injury; D004305:Dose-Response Relationship, Drug; D014453:Glucuronosyltransferase / Q000187:drug effects / Q000378:metabolism; D005978:Glutathione / Q000378:metabolism; D007097:Imines / Q000378:metabolism; D008099:Liver / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008107:Liver Diseases / Q000473:pathology / Q000517:prevention & control*; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D011224:Prazosin / Q000494:pharmacology*; D020011:Protective Agents / Q000494:pharmacology*
chemical_list: D000316:Adrenergic alpha-Agonists; D000317:Adrenergic alpha-Antagonists; D018712:Analgesics, Non-Narcotic; D016227:Benzoquinones; D007097:Imines; D020011:Protective Agents; D000082:Acetaminophen; D014453:Glucuronosyltransferase; D000410:Alanine Transaminase; C028473:N-acetyl-4-benzoquinoneimine; D005978:Glutathione; D011224:Prazosin